Welcome to our dedicated page for Alx Oncology Holdings SEC filings (Ticker: ALXO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage biotechnology company developing investigational cancer therapies. Through these filings, investors can review the company’s official disclosures on financial performance, governance, risk factors and progress of its pipeline programs, including the CD47 inhibitor evorpacept and the EGFR-targeted antibody-drug conjugate ALX2004.
Annual reports on Form 10-K and quarterly reports on Form 10-Q typically describe ALX Oncology’s research and development activities, clinical trial portfolio, expenses related to programs such as evorpacept and ALX2004, and other information relevant to its status as a clinical-stage biotechnology company. These reports also discuss risks associated with drug development, regulatory approval and financing.
Current reports on Form 8-K are used by ALX Oncology to disclose material events. For example, the company has filed 8-Ks to furnish quarterly financial results and to announce changes in its board of directors and committee composition. Such filings may incorporate press releases as exhibits and provide timely updates on corporate developments.
Investors interested in insider transactions can review Forms 3, 4 and 5, which report holdings and changes in ownership by directors, officers and certain shareholders. Proxy statements on Schedule 14A offer additional insight into governance matters and executive compensation.
On Stock Titan, ALX Oncology’s SEC filings are updated as they become available from the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key sections and clarify technical language, making it easier to understand complex topics such as clinical trial disclosures, R&D spending and risk factor discussions related to the company’s oncology pipeline.
ALX Oncology Holdings Inc. director receives new stock option grant. Director Garland J. Scott was awarded a stock option covering 40,400 shares of ALX Oncology common stock on January 20, 2026. The option has an exercise price of $1.32 per share and was granted at no purchase price for the option itself. Following this award, Scott beneficially owns 40,400 derivative securities directly.
The option vests in 12 equal monthly installments beginning on February 20, 2026, providing gradual ownership over one year, and is scheduled to expire on January 19, 2036 if not exercised.
ALX Oncology Holdings Inc. director Alan B. Sandler reported a new stock option grant for 10,100 shares of common stock. The option has an exercise price of $1.32 per share and was awarded on January 20, 2026. According to the filing, these option shares vest in 12 equal monthly installments beginning on February 20, 2026, spreading vesting over one year. The option expires on January 19, 2036, and Sandler is shown as directly holding 10,100 derivative securities following this transaction, reflecting this newly granted award.
ALX Oncology Holdings Inc. director Daniel J. Curran reported a new stock option grant in a Form 4 filing. On January 20, 2026, he was awarded a stock option (right to buy) covering 16,833 shares of common stock at an exercise price of $1.32 per share. The option vests in 12 equal monthly installments beginning on February 20, 2026, providing steady monthly vesting over one year. The option expires on January 19, 2036, giving a long-term window to exercise. Following this grant, Curran beneficially owns 16,833 derivative securities directly.
ALX Oncology Holdings director Chris H. Takimoto received a grant of stock options on January 20, 2026. The award covers 40,400 stock options with an exercise price of $1.32 per share, giving the right to buy the company’s common stock at that price in the future. The options expire on January 19, 2036, providing a long-term incentive tied to the company’s share performance.
According to the filing, the 40,400 options vest in 12 equal monthly installments beginning on February 20, 2026. After this grant, Takimoto beneficially owns 40,400 derivative securities directly.
ALX Oncology Holdings Inc. director Rekha Hemrajani received a new stock option grant. On January 20, 2026, she was awarded options to purchase 40,400 shares of ALX Oncology common stock at an exercise price of $1.32 per share. These options were granted at no upfront cost and are held directly.
The options are scheduled to vest in 12 equal monthly installments, beginning on February 20, 2026, and will remain exercisable until January 19, 2036, if service and other applicable conditions are met. After this grant, Hemrajani beneficially owns 40,400 stock options for ALX Oncology common shares.
ALX Oncology Holdings Inc. reported an insider stock sale by Shelly Pinto, the company’s SVP, Finance and CAO. On 01/06/2026, Pinto sold 3,925 shares of common stock at a weighted average price of $1.11 per share, in multiple trades between $1.11 and $1.12.
According to the filing, the sale was made to cover the reporting person’s tax obligations related to the vesting of restricted stock units. After this transaction, Pinto beneficially owned 88,273 shares of ALX Oncology common stock, which includes 3,000 shares acquired under the company’s employee stock purchase plan on December 31, 2025.
ALX Oncology (ALXO) reported Q3 2025 results highlighted by lower operating expenses and a smaller loss. Operating expenses were $22.5 million versus $32.6 million a year ago, driven by research and development of $17.4 million and general and administrative of $5.1 million. Net loss was $22.1 million, or $0.41 per share, compared with $30.7 million, or $0.58 per share, in Q3 2024.
Liquidity and balance sheet: Cash, cash equivalents and investments totaled $66.5 million as of September 30, 2025. Net cash used in operating activities was $65.2 million for the nine-month period. The company recorded a $3.2 million impairment in 2025 related to a planned sublease of a Palo Alto facility. Term loan balances were $4.3 million current and $5.8 million non-current. Management believes existing capital resources will fund operations for at least twelve months after the statements are issued.
Pipeline update: An exploratory analysis from the ASPEN‑06 gastric/GEJ study identified CD47 overexpression as a predictive biomarker in patients with retained HER2 expression, with reported outcomes including 65.0% ORR vs 26.1%, 25.5 vs 8.4 months median DOR, and improvements in PFS and OS for Evo‑TRP versus TRP.
ALX Oncology Holdings Inc. reported that it issued a press release announcing its financial results for the third quarter and full year ended September 30, 2025. The press release is furnished as Exhibit 99.1.
The company furnished this information under Item 2.02. The materials, including Exhibit 99.1, are not deemed “filed” and are not subject to Section 18 liability, nor incorporated by reference unless expressly stated.
ALX Oncology (ALXO) reported an insider equity award. On October 14, 2025, the company granted its SVP, Finance and CAO an employee stock option for 140,000 shares of common stock at a $1.70 exercise price, recorded as a grant at $0 price and held directly.
The option vests in two steps: one‑third on April 30, 2026 and the remaining two‑thirds on October 31, 2026. Following the transaction, 140,000 derivative securities were beneficially owned.
ALX Oncology Holdings (ALXO) reported an insider equity award for its Chief Financial Officer on a Form 4. The filing shows a grant of 198,750 employee stock options on 10/14/2025 with an exercise price of $1.7 per share and an expiration date of 10/14/2035. The grant was recorded at a price of $0 for the derivative security, indicating an award rather than a purchase.
The vesting schedule splits the award into two tranches: one-third vests on April 30, 2026, and the remaining two-thirds vest on October 31, 2026. Following the transaction, the filing lists 198,750 derivative securities beneficially owned, held directly.